drugset / Trial / NCT06742281
A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults
Phase 2
Completed
432 enrolled
CyanVac LLC
Biomedical Advanced Research and Development Authority · collab
RandomizedSingle-groupQuadruple-blindTreatment
Summary
The purpose of this trial is to assess the safety and relative efficacy of CVXGA (CVXGA50), a KP.2 containing vaccine, compared to COMIRNATY® (COVID-19 Vaccine, mRNA; 2024-2025 Formula), a currently approved COVID-19 vaccine in the prevention of symptomatic, RT-PCR-confirmed SARS-CoV-2 infection. The trial will enroll up to 434 healthy participants.
Timeline
- Start
- 2024-12-05
- Primary completion
- 2026-06-15
- Completion
- 2026-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BNT162b2 | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | CVXGA50 | Vaccine | — | Intranasal |